Crossref
Long-term benefits of switching from oral to intravenous calcimimetics in patients on hemodialysis
Clinical Nephrology · 2023
DOI: 10.5414/cn111012 ↗Kurz gefasst
Fachartikel in der Zeitschrift Clinical Nephrology, 2023. Verfasst von Shohei Fukunaga und 4 weiteren Autor:innen. Hauptthemen laut MEDLINE: Chronic Kidney Disease-Mineral and Bone Disorder.
Abstract (Originalsprache)
Kein Abstract verfügbar.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Chronic Kidney Disease-Mineral and Bone DisorderMaleFemaleHumansMiddle AgedAgedRenal DialysisCalciumParathyroid HormonePhosphorus
Substanzen
CalciumParathyroid HormonePhosphorus
Zitieren
APA
Fukunaga, S., Egawa, M., Shiono, M., Ito, T., & Tanabe, K. (2023). Long-term benefits of switching from oral to intravenous calcimimetics in patients on hemodialysis. Clinical Nephrology. https://doi.org/10.5414/cn111012
Vancouver
Fukunaga S, Egawa M, Shiono M, Ito T, Tanabe K. Long-term benefits of switching from oral to intravenous calcimimetics in patients on hemodialysis. Clinical Nephrology. 2023. doi:10.5414/cn111012
BibTeX
@article{Fukunaga2023,
author = {Fukunaga, Shohei and Egawa, Masahiro and Shiono, Manabu and Ito, Takafumi and Tanabe, Kazuaki},
title = {Long-term benefits of switching from oral to intravenous calcimimetics in patients on hemodialysis},
journal = {Clinical Nephrology},
year = {2023},
doi = {10.5414/cn111012}
}
EUVIMED